RT Journal Article ID 356e2ffb0a73d4f1 A1 Khan, Iliyas A1 Gothwal, Avinash A1 Sharma, Ashok Kumar A1 Kesharwani, Prashant A1 Gupta, Lokesh A1 Iyer, Arun K. A1 Gupta, Umesh T1 PLGA Nanoparticles and Their Versatile Role in Anticancer Drug Delivery JF Critical Reviews™ in Therapeutic Drug Carrier Systems JO CRT YR 2016 FD 2016-09-19 VO 33 IS 2 SP 159 OP 193 K1 nanotechnology K1 PLGA K1 anticancer drugs K1 drug delivery K1 nanoparticles K1 targeting AB Nanotechnological advancement has become a key standard for the diagnosis and treatment of several complex disorders such as cancer by utilizing the enhanced permeability and retention effect and tumor-specific targeting. Synthesis and designing the formulation of active agents in terms of their efficient delivery is of prime importance for healthcare. The use of nanocarriers has resolved the undesirable characteristics of anticancer drugs such as low solubility and poor permeability in cells. Several types of nanoparticles (NPs) have been designed with the use of various polymers along or devoid of surface engineering for targeting tumor cells. All NPs include polymers in their framework and, of these, polylactide-co-glycolide (PLGA) is biodegradable and Food and Drug Administration approved for human use. PLGA has been used extensively in the development of NPs for anticancer drug delivery. The extensive use of PLGA NPs is promising for cancer therapy, with higher efficiency and less adverse effects. The present review focused on recent developments regarding PLGA NPs, the methods used for their preparation, their characterization, and their utility in the delivery of chemotherapeutic agents. PB Begell House LK https://www.dl.begellhouse.com/journals/3667c4ae6e8fd136,3e868ea50400cfbb,356e2ffb0a73d4f1.html